BACKGROUND: Fulvestrant produces a clinical benefit rate (CBR) of approximately 45% in tamoxifen-resistant, hormone receptor (HR)-positive metastatic breast cancer (MBC) and 32% in aromatase inhibitor (AI)-resistant disease. The farnesyltransferase inhibitor tipifarnib inhibits Ras signaling and has preclinical and clinical activity in endocrine therapy-resistant disease. The objective of this study was to determine the efficacy and safety of tipifarnib-fulvestrant combination in HR-positive MBC. PATIENTS AND METHODS: Postmenopausal women with no prior chemotherapy for metastatic disease received i.m. fulvestrant 250 mg on day 1 plus oral tipifarnib 300 mg twice daily on days 1-21 every 28 days. The primary end point was CBR. RESULTS: The CBR was 51.6% [95% confidence interval (CI) 34.0% to 69.2%] in 31 eligible patients and 47.6% (95% CI 26.3% to 69.0%) in 21 patients with AI-resistant disease. A futility analysis indicated that it was unlikely to achieve the prespecified 70% CBR. Tipifarnib dose modification was required in 8 of 33 treated patients (24%). CONCLUSIONS: The target CBR of 70% for the tipifarnib-fulvestrant combination in HR-positive MBC was set too high and was not achieved. The 48% CBR in AI-resistant disease compares favorably with the 32% CBR observed with fulvestrant alone in prior studies and merit further clinical and translational evaluation.
BACKGROUND:Fulvestrant produces a clinical benefit rate (CBR) of approximately 45% in tamoxifen-resistant, hormone receptor (HR)-positive metastatic breast cancer (MBC) and 32% in aromatase inhibitor (AI)-resistant disease. The farnesyltransferase inhibitor tipifarnib inhibits Ras signaling and has preclinical and clinical activity in endocrine therapy-resistant disease. The objective of this study was to determine the efficacy and safety of tipifarnib-fulvestrant combination in HR-positive MBC. PATIENTS AND METHODS: Postmenopausal women with no prior chemotherapy for metastatic disease received i.m. fulvestrant 250 mg on day 1 plus oral tipifarnib 300 mg twice daily on days 1-21 every 28 days. The primary end point was CBR. RESULTS: The CBR was 51.6% [95% confidence interval (CI) 34.0% to 69.2%] in 31 eligible patients and 47.6% (95% CI 26.3% to 69.0%) in 21 patients with AI-resistant disease. A futility analysis indicated that it was unlikely to achieve the prespecified 70% CBR. Tipifarnib dose modification was required in 8 of 33 treated patients (24%). CONCLUSIONS: The target CBR of 70% for the tipifarnib-fulvestrant combination in HR-positive MBC was set too high and was not achieved. The 48% CBR in AI-resistant disease compares favorably with the 32% CBR observed with fulvestrant alone in prior studies and merit further clinical and translational evaluation.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: L R Kelland; V Smith; M Valenti; L Patterson; P A Clarke; S Detre; D End; A J Howes; M Dowsett; P Workman; S R Johnston Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: Stephen R D Johnston; Julia Head; Sunil Pancholi; Simone Detre; Lesley-Ann Martin; Ian E Smith; Mitch Dowsett Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: A Howell; J F R Robertson; J Quaresma Albano; A Aschermannova; L Mauriac; U R Kleeberg; I Vergote; B Erikstein; A Webster; C Morris Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: C K Osborne; J Pippen; S E Jones; L M Parker; M Ellis; S Come; S Z Gertler; J T May; G Burton; I Dimery; A Webster; C Morris; R Elledge; A Buzdar Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: Stephen R D Johnston; Vladimir F Semiglazov; George M Manikhas; Dominique Spaeth; Gilles Romieu; David J Dodwell; Andrew M Wardley; Patrick Neven; Annick Bessems; Youn C Park; Peter M De Porre; Juan J Perez Ruixo; Angela J Howes Journal: Breast Cancer Res Treat Date: 2007-09-13 Impact factor: 4.872
Authors: Stephen R D Johnston; Tamas Hickish; Paul Ellis; Stephen Houston; Lloyd Kelland; Mitch Dowsett; Janine Salter; Bart Michiels; Juan Jose Perez-Ruixo; Peter Palmer; Angela Howes Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: L M Berstein; H Zheng; W Yue; J-P Wang; A E Lykkesfeldt; F Naftolin; H Harada; M Shanabrough; R J Santen Journal: Endocr Relat Cancer Date: 2003-06 Impact factor: 5.678
Authors: Patience Odeniyide; Marielle E Yohe; Kai Pollard; Angelina V Vaseva; Ana Calizo; Lindy Zhang; Fausto J Rodriguez; John M Gross; Amy N Allen; Xiaolin Wan; Romel Somwar; Karisa C Schreck; Linda Kessler; Jiawan Wang; Christine A Pratilas Journal: Oncogene Date: 2022-04-22 Impact factor: 8.756